Headache Medication and the COVID-19 Pandemic

Overview

Journal J Headache Pain

Publisher Biomed Central

Date 2020 Apr 27

PMID 32334535

Citations 36

Authors

Antoinette MaassenVanDenBrink

Tessa de Vries

A H Jan Danser

Affiliations

Soon will be listed here.

Abstract

The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.

Citing Articles

Persistent headache after COVID-19: Pathophysioloy, clinic and treatment.

Membrilla J, Caronna E, Trigo-Lopez J, Gonzalez-Martinez A, Layos-Romero A, Pozo-Rosich P Neurol Perspect. 2024; 1:S31-S36.

PMID: 38620971 PMC: 8669731. DOI: 10.1016/j.neurop.2021.10.003.

[Neurological complications in critical patients with COVID-19].

Abenza-Abildua M, Ramirez-Prieto M, Moreno-Zabaleta R, Arenas-Valls N, Salvador-Maya M, Algarra-Lucas C Neurologia. 2024; 35(9):621-627.

PMID: 38620654 PMC: 7402100. DOI: 10.1016/j.nrl.2020.07.014.

[Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology's Headache Study Group].

Morollon N, Belvis R, De Dios A, Pages N, Gonzalez-Oria C, Latorre G Neurologia. 2024; 35(9):628-632.

PMID: 38620330 PMC: 7386293. DOI: 10.1016/j.nrl.2020.07.007.

Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID.

Seo J, Kim S, Kim Y, Kim E, Kim T, Kim T Infect Chemother. 2024; 56(1):122-157.

PMID: 38527781 PMC: 10990882. DOI: 10.3947/ic.2024.0024.

[Subtle and subclinical neurological findings in patients with SARS-CoV-2].

Martinez-Pina D, San Juan-Orta D, Gonzalez-Guevara E, Vazquez-Diaz C, Hernandez-Gonzalez M, Sosa-Ramos J Rev Med Inst Mex Seguro Soc. 2023; 61(6):767-775.

PMID: 37995329 PMC: 10712932. DOI: 10.5281/zenodo.10064309.

References

Pomes L, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P . Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019; 20(1):56. PMC: 6734220. DOI: 10.1186/s10194-019-1010-3. View

Li W, Moore M, Vasilieva N, Sui J, Wong S, Berne M . Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965):450-4. PMC: 7095016. DOI: 10.1038/nature02145. View

Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q . Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015; 131(2):97-106. DOI: 10.1159/000375362. View

Serfozo P, Wysocki J, Gulua G, Schulze A, Ye M, Liu P . Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent. Hypertension. 2019; 75(1):173-182. PMC: 7286421. DOI: 10.1161/HYPERTENSIONAHA.119.14071. View

Arendse L, Danser A, Poglitsch M, Touyz R, Burnett Jr J, Llorens-Cortes C . Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev. 2019; 71(4):539-570. PMC: 6782023. DOI: 10.1124/pr.118.017129. View

Loder E, Rizzoli P . Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018. Headache. 2018; 58 Suppl 3:218-229. DOI: 10.1111/head.13375. View

Ferrario C, Jessup J, Chappell M, Averill D, Brosnihan K, Tallant E . Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111(20):2605-10. DOI: 10.1161/CIRCULATIONAHA.104.510461. View

Soler M, Ye M, Wysocki J, William J, Lloveras J, Batlle D . Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2008; 296(2):F398-405. DOI: 10.1152/ajprenal.90488.2008. View

Shamliyan T, Choi J, Ramakrishnan R, Miller J, Wang S, Taylor F . Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013; 28(9):1225-37. PMC: 3744311. DOI: 10.1007/s11606-013-2433-1. View

10.

Wang X, Ye Y, Gong H, Wu J, Yuan J, Wang S . The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol. 2016; 97:180-90. DOI: 10.1016/j.yjmcc.2016.05.012. View

11.

Panati K, Narala V . COVID-19 Outbreak: an Update on Therapeutic Options. SN Compr Clin Med. 2020; 2(4):379-380. PMC: 7110269. DOI: 10.1007/s42399-020-00264-6. View

12.

Danser A, Epstein M, Batlle D . Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020; 75(6):1382-1385. PMC: 7225046. DOI: 10.1161/HYPERTENSIONAHA.120.15082. View

13.

Fang L, Karakiulakis G, Roth M . Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020; 8(4):e21. PMC: 7118626. DOI: 10.1016/S2213-2600(20)30116-8. View

14.

Kurth T, Winter A, Eliassen A, Dushkes R, Mukamal K, Rimm E . Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016; 353:i2610. PMC: 4887613. DOI: 10.1136/bmj.i2610. View